News
Wei Xie, Shuanghuan Liu, Guanqiao Li, Huiyan Xu, Liyun Zhou. The evolving treatment paradigm of lung cancer in China[J]. Acta Pharmaceutica Sinica B, 2022, 12(3): 1536-1537

The evolving treatment paradigm of lung cancer in China
Wei Xiea, Shuanghuan Liub, Guanqiao Lic, Huiyan Xua, Liyun Zhoua
a. Pharmcube (Beijing) Co., Ltd., Beijing 100020, China;
b. National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
c. Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100089, China
Abstract:
Key words:   
Received: 2021-12-14     Revised:
DOI: 10.1016/j.apsb.2022.01.010
Corresponding author: Liyun Zhou,E-mai:zhouliyun@pharmcube.com     Email:zhouliyun@pharmcube.com
Author description:
Service
PDF(KB) Free
Print
0
Authors
Wei Xie
Shuanghuan Liu
Guanqiao Li
Huiyan Xu
Liyun Zhou

References:
[1] National Health Commission of the People’s Republic of China. China Health Statistics 2021. Beijing:Peking Union Medical College Press; 2021
[2] Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol 2021;18:547-557
[3] Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559
[4] Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med 2018;6:863-873
[5] Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wu L, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018;19:139-148
[6] Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020;383:1711-1723
[7] He J, Su C, Liang W, Xu S, Wu L, Fu X, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med 2021;9:1021-1029
[8] Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398:1344-1357
Similar articles: